摘要
目的:评价我院2009年-2012年口服降糖药物使用情况,为临床合理选用口服降糖药物提供依据。方法:应用DDDs排序、金额排序、DDC数据对我院2009年-2012年各类口服降糖药物及常用品种的使用量进行统计、分析。结果:4年间,我院口服降糖药物的DDDs呈上升趋势,总增幅为40.99%,各年度总DDDs分别为2383448.16、2690553.74、3072970.07、3360334.65。DDDs排名处于前5位的是阿卡波糖片、格列美脲片、盐酸二甲双胍片、格列喹酮片、瑞格列奈片(诺和龙)。口服降糖药物在4年间的总销售金额呈上升趋势,从2009年的20314119.95元逐渐上升到2012年的26573385.15元,总增幅为30.81%。磺酰脲类药物的日均消费(DDC)值最低,平均为3.80元/日。结论:2009年-2012年我院口服降糖药物的使用仍然以磺酰脲类、α糖苷酶抑制剂、双胍类为主。DPP-4抑制剂作为新型降糖药物已逐渐投入临床使用。
Objective： To analyze the consumption of oral antidiabetic drugs （OAD） in our hospital from 2009 to 2012, and to provide scientific evidence for the appropriate use of oral antidiabetic drugs in treatment. Method： The DDDs, sales amount, DDC of different types of OADs and commonly used OADs were analyzed and sorted. Results： The DDDs of OADs in our hospital increased slightly in 4 years with the total increase of 40.99%. The DDDs from 2009 to 2012 were 2383448.16, 2690553.74, 3072970.07 and 3360334.65 respectively. Acarbose, glimepiride, metformin, gliquidone, repaglinide took the top five places of DDDs. The total amount of sales of OADs in our hospital increased in 4 years, from 20,314,119.95 yuan in 2009 to 26,573,385.15 yuan in 2012, with a total increase of 30.81%. Defined daily consumption （DDC） of sulphonylureas was the lowest, with an average of 3.80 yuan per day. Conclusion： Sulfonylurea, cL-glucosidase inhibitors, biguanides were the mainly used oral antidiabetic drugs during 2009-2012 in our hospital. As a novel antidiabetic drug, DPP-4 inhibitor had been gradually accepted by doctor and patient.
出处
《药品评价》
CAS
2013年第22期14-18,44,共6页
Drug Evaluation
